Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 6/20 | 0.36 |
| ▸ | CES2 | O00748 | 5/20 | 0.36 |
| ▸ | BLM | P54132 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | LDHA | P00338 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.35 |
| ▸ | GMNN | O75496 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30439643 | 0.94 | FAAH (0.50) | FAAHL3MBTL1CES1CES2BLM | |
| SCHEMBL28721888 | 0.87 | FAAH (0.54) | FAAHCES1CES2BLMKMT2A | |
| SCHEMBL984694 | 0.83 | — | — | |
| SCHEMBL8921255 | 0.79 | KMT2A (0.46) | FAAHL3MBTL1BLMKMT2AALOX15 | |
| Hydrochloric Acid SCHEMBL5736439 | 0.79 | LMNA (0.44) | FAAHL3MBTL1BLMKMT2AALOX15 | |
| SCHEMBL6267121 | 0.79 | OR51E2 (0.48) | FAAHCES1CES2BLMKMT2A | |
| SCHEMBL28907900 | 0.78 | CES2 (0.55) | FAAHCES1CES2KMT2AALOX15 | |
| SCHEMBL5067376 | 0.77 | — | — | |
| SCHEMBL8725568 | 0.77 | — | — | |
| SCHEMBL11517057 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383856-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-11-21 | — | — | US | claimed |
| US-20240376055-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-11-14 | — | — | US | claimed |
| US-20240270715-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-08-15 | — | — | US | claimed |
| EP-4192813-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-08-14 | — | — | EP | claimed |
| EP-4192814-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-08-07 | — | — | EP | claimed |
| EP-3405477-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-06-07 | — | — | EP | claimed |
| US-20240383856-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-11-21 | — | — | US | disclosed |
| US-20240376055-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-11-14 | — | — | US | disclosed |
| US-20240270715-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-08-15 | — | — | US | disclosed |
| EP-4192813-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-08-14 | — | — | EP | disclosed |
| WO-2023110138-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-06-22 | — | — | WO | disclosed |
| EP-4192814-A1 | INHIBITORS OF TRANSGLUTAMINASES | Zedira GmbH (DE) | 2023-06-14 | — | — | EP | disclosed |
| WO-2023275337-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383856-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | FAAH 1123/4885L3MBTL1 3414/4885CES1 178/4885 |
| US-20240376055-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | FAAH 1123/4885L3MBTL1 3414/4885CES1 178/4885 |
| US-20240270715-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | FAAH 1123/4885L3MBTL1 3414/4885CES1 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.